Genomictree Inc. (KOSDAQ:228760)
South Korea · Delayed Price · Currency is KRW 16,960
+200 (1.19%)
Apr 10, 2026, 3:30 PM KST
Genomictree Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 3,760 | 2,362 | 3,418 | 29,866 | 5,140 |
Other Revenue | - | - | 0 | - | - |
| 3,760 | 2,362 | 3,418 | 29,866 | 5,140 | |
Revenue Growth (YoY) | 59.17% | -30.89% | -88.55% | 481.09% | 314.87% |
Cost of Revenue | 3,061 | 3,108 | 3,720 | 4,891 | 2,641 |
Gross Profit | 699 | -745.56 | -301.62 | 24,974 | 2,499 |
Selling, General & Admin | 7,279 | 8,757 | 10,936 | 14,024 | 8,524 |
Research & Development | 3,788 | 4,942 | 4,366 | 5,446 | 2,812 |
Amortization of Goodwill & Intangibles | 89.19 | 121.18 | 174.05 | 173.92 | 165.5 |
Other Operating Expenses | 411.58 | 267.92 | 894.91 | 223.09 | 384.93 |
Operating Expenses | 11,997 | 14,568 | 17,002 | 22,569 | 12,354 |
Operating Income | -11,298 | -15,313 | -17,303 | 2,405 | -9,855 |
Interest Expense | -338.07 | -294.65 | -2,054 | -5,382 | -4,606 |
Interest & Investment Income | 3,169 | 3,361 | 4,829 | 3,610 | 4,147 |
Currency Exchange Gain (Loss) | -102.84 | 565.25 | -21.87 | 498.93 | 831.9 |
Other Non Operating Income (Expenses) | 231.26 | 468.31 | 817.71 | -4,682 | 112.85 |
EBT Excluding Unusual Items | -8,339 | -11,214 | -13,733 | -3,550 | -9,369 |
Gain (Loss) on Sale of Investments | -649.36 | 828.71 | -328.33 | -2,097 | -2,072 |
Gain (Loss) on Sale of Assets | -117.47 | -4.46 | - | -92.05 | 17.1 |
Asset Writedown | -7.96 | - | - | - | - |
Other Unusual Items | - | - | 4,558 | 2,045 | - |
Pretax Income | -9,114 | -10,389 | -9,503 | -3,693 | -11,424 |
Income Tax Expense | 11.47 | 1.09 | -496.61 | 2,544 | 0.92 |
Earnings From Continuing Operations | -9,125 | -10,390 | -9,007 | -6,237 | -11,425 |
Minority Interest in Earnings | 139.32 | 148.02 | 250.69 | -393.43 | - |
Net Income | -8,986 | -10,242 | -8,756 | -6,631 | -11,425 |
Net Income to Common | -8,986 | -10,242 | -8,756 | -6,631 | -11,425 |
Shares Outstanding (Basic) | 24 | 24 | 22 | 21 | 21 |
Shares Outstanding (Diluted) | 24 | 24 | 27 | 21 | 21 |
Shares Change (YoY) | 0.63% | -9.93% | 26.28% | 1.68% | 3.30% |
EPS (Basic) | -374.00 | -429.00 | -390.66 | -315.89 | -553.38 |
EPS (Diluted) | -374.00 | -429.00 | -448.80 | -316.00 | -553.38 |
Free Cash Flow | -12,919 | -16,118 | -11,120 | 2,523 | -18,593 |
Free Cash Flow Per Share | -537.70 | -675.09 | -419.50 | 120.20 | -900.62 |
Gross Margin | 18.59% | -31.56% | -8.82% | 83.62% | 48.62% |
Operating Margin | -300.47% | -648.24% | -506.25% | 8.05% | -191.75% |
Profit Margin | -238.98% | -433.57% | -256.17% | -22.20% | -222.28% |
Free Cash Flow Margin | -343.58% | -682.29% | -325.32% | 8.45% | -361.76% |
EBITDA | -10,233 | -14,128 | -16,125 | 3,740 | -8,833 |
EBITDA Margin | -272.15% | - | - | 12.52% | -171.86% |
D&A For EBITDA | 1,065 | 1,186 | 1,178 | 1,335 | 1,022 |
EBIT | -11,298 | -15,313 | -17,303 | 2,405 | -9,855 |
EBIT Margin | - | - | - | 8.05% | -191.75% |
Advertising Expenses | 415.1 | 871.86 | 932.39 | 964.91 | 1,119 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.